Background {#s1}
==========

Various glomerular diseases can be caused by the deposition of monoclonal immunoglobulin G (IgG). Renal disease related to the deposition of monoclonal IgG containing both heavy and light chains can occur in type 1 cryoglobulinemia, Randall-type light- and heavy-chain deposition disease (LHCDD), light- and heavy-chain amyloidosis and immunotactoid glomerulonephritis \[[@SFV105C1]--[@SFV105C5]\]. Proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) is a relatively newly described entity mimicking immune complex glomerulonephritis (GN) that does not conform to any of those subtypes. It represents a form of proliferative GN with electron-dense deposits (EDDs) localized to glomeruli and immunofluorescence (IF) findings of monoclonal IgG deposits. Recurrent PGNMID in the renal allograft has been described in a few case series \[[@SFV105C6]--[@SFV105C8]\]. In this article we present the clinical--pathologic features of three cases of PGNMID in the renal allograft showing the variable course and manifestation of the disease. Our three cases, like most other reported cases, have no bone marrow involvement and no evidence of monoclonal protein on electrophoresis and immunofixation studies. Thus, this makes disease activity and remission status monitoring very difficult to assess.

Case 1 {#s1a}
------

A 61-year-old Caucasian female developed end-stage kidney disease (ESKD) secondary to membranoproliferative glomerulonephritis (MPGN) based on a native kidney biopsy in 2001, with no further information about IF or electron microscopy (EM). In December 2006, her serum creatinine (SCr) was 530 μmol/L and she underwent a preemptive unrelated living kidney transplantation. In 2014, she was found to have a random urine protein/gram creatinine (UPCR) of ∼452 mg/mmol and an SCr of 132 μmol/L, up from 106 μmol/L. Her workup for a lymphoproliferative disorder was negative, as was her serologic workup (see Table [1](#SFV105TB1){ref-type="table"}). On biopsy, IF showed diffuse granular positivity for IgG, C3 and C1q. Deposits were composed of IgG3-kappa with no peritubular C4d. EM showed EDDs, mostly in the mesangium and subendothelial regions (please see Figures[ 1](#SFV105F1){ref-type="fig"}--[7](#SFV105F7){ref-type="fig"}). She received three cycles of bortezomib. UPCR was persistently elevated at 565 mg/mmol. She was later switched to Carfilzomib, as she developed acute kidney injury with SCr up to 247 μmol/L; after completion of therapy her SCr was 150 μmol/L. Table 1.Clinical data of post--kidney transplant recipients with PGNMIDPatient\# 1\# 2\# 3\# 4 \[[@SFV105C6]\]\# 5 \[[@SFV105C6]\]\# 6 \[[@SFV105C6]\]Age (years)617440616868Race/sexCaucasian/femaleCaucasian/maleHispanic/femaleCaucasian/maleCaucasian/femaleCaucasian/femaleCause of ESKDMPGNPGMIDMPGNPGNMIDUnclear---nephrotic range proteinuriaPolycystic kidney disease (PKD)Transplant typeUnrelated living donorDeceased donorDeceased donorDeceased donorRelated living donorDeceased donorISFK506, prednisone, MMFFK506, prednisone, MMFFK506 and azathioprineMMF, rapamycinMMF, rapamycinPrednisone, cyclosporineBaseline SCr (μmol/L)10626496.8114132132SCr at biopsy (μmol/L)132396114237281228Time from transplant to diagnosis of recurrent or *de novo* PGNMID (months)9861321321158Proteinuria (mg/mmol)4001002087050150Hematuria1+3+2+2+2+1+Serum complementNormalNormalNormalNormalNormalNormalCryoglobulinNegativeNegativeNegativen/an/an/aHepatitis BNegativeNegativeNegativeNegativeNegativeNegativeHepatitis CNegativeNegativeNegativeNegativeNegativeNegativeHIVNon-reactiveNon-reactiveNon-reactiveNon-reactiveNon-reactiveNon-reactiveMonoclonal protein spikeNegativeNegativeNegativeNegativeNegativeNegativePattern of injuryEC on both biopsies with a crescent on the second biopsyNative biopsy: 1st -- ATN\
2nd -- EC\
Transplant biopsy: MPMPMPGN-likeMPMPGN-likeNumber of glomeruli sclerosedNone on first, 3 of 20 on second13/364 of 101 of 91 of 275 of 8Interstitial fibrosisNone on first and 15% on second50%15%1+3+3+IgG subtype kappa or lambdaIgG3-kappaNative: IgG lambda (subtype not available)\
2nd transplant: IgG3-lambdaIgG3-kappaIgG3-kappa, mild lambdaIgG3-kappaIgG1-kappaElectron microscopy depositsEDM, EDS on both biopsiesNative biopsy: EDS, EDM\
Transplant biopsy: EDMEDM, EDSMPGN-likeMPMPGN-likeBone marrow biopsyPositive stain for plasma cells for CD138 ∼5% cellularity; no staining for kappa and lambda light chain by *in situ* hybridizationPositive stain for plasma cells for CD138 \<5% cellularity; no staining for kappa and lambda light chain by *in situ* hybridization (pre-transplant)Not done due to stability of kidney functionNoneNoneNoneTreatmentBortezomib ×3 doses, dexamethasone ×3 dosesPatient opted for noneNo changeNo changeChange to MMF and prednisoneNo changeOutcome after allograft biopsy: SCr (μmol/L)149, proteinuria 600 mg/mmol\
Remains on IS as aboveEnd-stage kidney disease114\
proteinuria 10 mg/mmol\
Remains on IS as aboveFatal MI after 20 months of kidney biopsyDied with cryptococcal meningitis 15 months after biopsyEnd-stage kidney diseaseFollow-up (months) after biopsy17336201520Patient\# 7 \[[@SFV105C6]\]\# 8 \[[@SFV105C7]\]\# 9 \[[@SFV105C7]\]\# 10 \[[@SFV105C7]\]\# 11 \[[@SFV105C7]\]\# 12 \[[@SFV105C8]\]Age245560743866Race/sexCaucasian/femaleCaucasian/maleCaucasian/femaleCaucasian/femaleCaucasian/femaleCaucasian/femaleCause of ESKDDiabetic nephropathyPGNMIDPGNMIDPGNMIDPGNMIDPGNMIDTransplant typeSimultaneous kidney--pancreasUnrelated living donorDeceased donorUnrelated living donorUnrelated living donorDeceased donorISFK506, prednisone, MMFFK506, prednisone, MMFFK506, prednisone, MMFFK506, prednisone, MMFFK506, prednisone, MMFFK506, prednisone, MMF stopped at 1 monthBaseline SCr (μmol/L)15816710612379.260.7SCr at biopsy (μmol/L)290246326422106176Time from transplant to diagnosis of recurrent or *de novo* PGNMID (months)4312221564318Proteinuria (mg/mmol)170807405806330Hematuria3+YesYesYesNo3+Serum complementNormalNormalLow C3 and C4Low C3 and C4Normaln/aCryoglobulinn/aNegativeNegativeNegativeNot doneNegativeHepatitis BNegativeNegativeNegativeNegativeNegativeNegativeHepatitis CNegativeNegativeNegativeNegativeNegativeNegativeHIVNon-reactiveNon-reactiveNon-reactiveNon-reactiveNon-reactiven/aMonoclonal protein spikeNegativeNegativeNegativeNegativeNegativePattern of injuryMPGN-likeFirst two biopsies showed MP, third showed diffuse EC and fourth showed focal proliferativeDiffuse EC on both with diffuse on first and focal on second biopsyFirst biopsy showed diffuse EC and exudative GN, next two biopsies with MPMinimal to mild MPEC with crescentsNumber of glomeruli sclerosed8 of 133/37 sclerosed, 16/27 crescentsInterstitial fibrosis2+MildMildMild then moderateMild then moderateIgG subtype kappa or lambdaIgG3-kappaIgG3-kappaIgG3-kappaIgG3-lambdaIgG3-kappaKappa (subtype not available)Electron microscopy depositsMPGN-likeFirst two biopsies showed EDM, and EDM and EDS on last twoEDM, EDSFirst and third showed EDS and second showed EDM and EDSEDM in first two biopsies and EDM and EDS in others; third and fifth biopsies showed Banff 1AEDM and parietal depositsBone marrow biopsyNoneNoneNoneNoneNoneNoneTreatmentNo changePrednisone, oral cyclophosphamide for 6 monthsMethylprednisolone with prednisone, rituximab ×2 doses, lisinoprilMethylprednisolone with prednisone, rituximab ×1 dose, with plasmapheresis ×4 and HD ×3Methylprednisolone for ACR, rituximab ×2 dosesPlasmapheresis, IVIG 0.5 g/kg/day with methylprednisolone total 850 mg, MMF 1.5 g/dayOutcome after allograft biopsy: SCr (μmol/L)29020296.811420296.8, transplant nephrectomy in the setting of sepsis 6 months post-treatment with biopsy showing resolution of disease despite nephrectomy, disappearance of EC and cellular crescents, IF staining remained kappaFollow-up (months) after biopsy'Short'151183636[^1] Fig. 1.Mild chronic changes of tubular atrophy and interstitial fibrosis. Low power light microscopy, periodic acid--Schiff stain. Fig. 2.The preserved glomeruli are enlarged and hypercellular. The increase in cells includes increased mononuclear elements within the expanded mesangial areas and many mononuclear inflammatory cells within the glomerular capillary lumens. As a result, the capillary tufts have a distinctly lobulated appearance. Magnification ×200, hematoxylin and eosin stain. Fig. 3.The peripheral capillary walls are distorted and thickened, often with the formation of double contours or basement membranes with a chain-like appearance. Magnification ×400, periodic acid--Schiff stain. Fig. 4.Diffuse irregular granular and pseudolinear deposition of IgG (3+/4+). No staining is found in Bowman\'s capsule or the tubular basement membranes. Magnification ×200, IF micrograph. Fig. 5.Kappa light chains stain strongly positive (3+/4+) along the peripheral capillary walls and mesangial areas. Lambda light chains are negative in the deposits. Magnification ×400, IF micrograph. Fig. 6.IF staining for the IgG subtypes shows intense glomerular positivity for (**C**) IgG3 with negative staining for (**A**), IgG1 (**B**) IgG2 and (**D**) IgG3. Fig. 7.Glomerular capillaries are greatly distorted and thickened by the presence of numerous, sometimes large and/or confluent subendothelial electron-dense deposits. The electron-dense deposits have a variegated ('two-toned') appearance and are finely granular, but they do not show organized substructures. Magnification ×12 000, electron micrograph.

Case 2 {#s1b}
------

A 74-year-old Caucasian male developed ESKD secondary to PGNMID seen on a native biopsy on September 2009. He received bortezomib and dexamethasone; however, he developed ESKD requiring hemodialysis (HD) after three doses. He received a diseased donor transplant (DDT) in May 2013, with his course complicated by biopsy-proven acute tubular injury. His SCr improved to 265 μmol/L until 6 months post-transplant, at which time his SCr was ∼ 530 μmol/L. He had a negative M spike and negative serologies. IF from his biopsy showed positivity for IgG3, C3, C1q and lambda light chains. Kappa was negative, as were peritubular capillaries for C4d (see Table [1](#SFV105TB1){ref-type="table"}). His kidney disease progressed and he declined therapy and restarted HD 9-month post-transplantation.

Case 3 {#s1c}
------

A 40-year-old Hispanic female received a DDT in June 2001 after developing ESKD. In 1995, she had biopsy-proven type 1 MPGN. There were no IF data for reevaluation. In June 2012, she had hematuria and her SCr was 114 μmol/L, up from her baseline SCr of 97 μmol/L. UPCR was less than 20 mg/mmol. Her allograft biopsy showed a mesangioproliferative pattern of injury by light microscopy (see Table [1](#SFV105TB1){ref-type="table"}). IF revealed mesangial deposits restricted to IgG3-kappa. Her plasma cell dyscrasia workup was negative as was her serologic workup. SCr is stable at 115 μmol/L with UPCR at 10 mg/mmol.

Discussion {#s2}
==========

PGNMID, a novel type that does not conform to any subtypes, was described initially in 2004 \[[@SFV105C9]\] followed by the largest series of 37 cases in 2009 \[[@SFV105C10]\]. The disease manifests with proteinuria, hematuria and variable degrees of renal impairment. Disease incidence is 0.17% \[[@SFV105C10]\]. Most of the patients have a normal workup for paraproteinemia. Histologic patterns by light microscopy were mostly membranoproliferative with a lobular nodular pattern of injury followed by an endocapillary proliferative pattern. EM revealed granular, nonorganized deposits mostly in the mesangium and subendothelium. IF demonstrated granular glomerular deposits that stained for a single light-chain isotype and a single heavy-chain subtype, most commonly IgG3-kappa \[[@SFV105C7], [@SFV105C10]\]. More than 40 additional cases were identified by other groups \[[@SFV105C6], [@SFV105C11]--[@SFV105C19]\].

Recently, recurrent PGNMID after kidney transplantation has been reported as case reports or small series of one to four patients \[[@SFV105C6]--[@SFV105C8]\]. The recurrent disease manifested clinically as allograft dysfunction, hematuria and proteinuria. No patient had a detectable M spike in serum or urine. Complements were normal. Hepatitis B, hepatitis C and cryoglobulins were negative. Histologic features were mostly endocapillary proliferative GN or mesangial proliferative GN \[[@SFV105C7]\].

Of the patients reported (see Table [1](#SFV105TB1){ref-type="table"}), the average age was 57 years. Patients tended to be Caucasian (11/12) and female (10/12). Disease diagnosis averaged 60 months from transplantation. The baseline SCr following transplantation was 128 μmol/L and at disease diagnosis was 246 μmol/L. IgG3-kappa was the predominant IgG identified (IgG3 11/12 and kappa 10/12). Three patients ended up with ESKD and two died related to infectious complications. There was an average of 24 months of follow-up after diagnosis.

Disease recurrence can range from an average of 3.8 months in some series \[[@SFV105C7]\] up to 2 years after kidney transplantation \[[@SFV105C5], [@SFV105C7]\]. The risk of recurrence is difficult to estimate based on the small number of patients and the absence of protocol biopsies in most cases. Moreover, the immunosuppressive treatment may have an impact on disease course that may be difficult to isolate. Disease recurrence can have a variable outcome, with some patients having persistent renal impairment and some progressing to end-stage renal disease. Our three cases reflect this variable disease course.

PGNMID is often missed or underdiagnosed, with diagnoses of MPGN or even light- and heavy-chain deposition disease (LHCDD). Some cases like case 1 and case 3 were originally diagnosed as MPGN type 1 before this entity was well established. In many instances, IF and EM were not available, nor was staining for light chains. PGNMID and LHCDD are similar in many aspects, however, the pathogenesis is different. LHCDD results from the deposition of heavy and light chains in the glomerular and tubular basement membrane, as opposed to PGNMID, where the deposits are intact monoclonal immunoglobulin affecting only the glomeruli. PGNMID is characterized by granular EDDs, in contrast to LHCDD, where those are mostly powdery deposits. IgG3 was the IgG isoform identified most often in prior studies to be deposited in the glomeruli despite comprising only 8% of the total immunoglobulin in the serum \[[@SFV105C6], [@SFV105C7]\]. Limitation to IgG3 in our three cases confirms the specific predilection for IgG3 to precipitate and self-aggregate in the glomeruli given its properties of high molecular weight, positive charge and complement activation capacity \[[@SFV105C7]\].

Monoclonal gammopathy of renal significance is an increasingly recognized entity in patients who are found to have monoclonal protein with renal involvement. Patients who do not fulfill the criteria for multiple myeloma have traditionally been labeled as monoclonal gammopathy of undetermined significance given the limited diagnostic schema, and consequently no therapy has been offered. However, it is more established now that addressing this clonal proliferation may preserve the kidneys and potentially prevent disease recurrence. There was no monoclonal protein identified in our patients, nor the other cases. Nevertheless, a thorough workup is strongly recommended as it may impact the therapeutic plan \[[@SFV105C20]\].

Cases of *de novo* PGNMID on kidney allografts have been reported. One case series described the occurrence of PGNMID in two patients after transplantation. One patient with polycystic kidney disease was diagnosed with PGNMID 13 years after kidney transplantation. Another patient had diabetes nephropathy leading to ESKD and developed *de novo* PGNMID 3 years after transplantation \[[@SFV105C6]\]. While having different primary pathology supports that allograft disease is *de novo*, late occurrence does not exclude recurrence, as kidney transplant recipients may have a different disease course and disease activity due to immunosuppressive drugs.

Based on a pathogenesis hypothesis, it would seem rational to treat with immunomodulating therapy. Unfortunately, there is no proven effective treatment. Transplant recipients are on continuous immunosuppressive therapy. Aggressive immunosuppression with rituximab/or cyclophosphamide combined with steroids has been used \[[@SFV105C7]\]. Bortezomib was tried in one patient with native disease in one series \[[@SFV105C10]\], however, not in any transplant patients. Given the role of monoclonal Ig in the disease pathogenesis, bortezomib was tried in two of our patients, one with disease in the native kidney prior to transplant (case 2) and one with disease recurrence following transplant (case 1), with no favorable response.

Conclusion {#s3}
==========

PGNMID is becoming a more recognized entity, with more patients being evaluated for renal transplant. This disease has a wide spectrum of clinical presentations. Distinguishing this entity from other diseases may have an impact on outcome and treatment. Evaluating these patients for transplant eligibility may be challenging in the absence of distinct data of remission given that most patients have normal bone marrow biopsy and no monoclonal band on serum and urine testing. Data are scarce in terms of follow-up and treatment. More long-term studies will be needed to further investigate disease course and response to therapy.
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[^1]: MPGN, membranoproliferative glomerulonephritis; PGNMID, proliferative glomerulonephritis and monoclonal immunoglobulin deposits; MP, mesangial proliferative; EP, endothelial proliferative; EC, endocapillary proliferative; SCr, serum creatinine; MMF, mycophenolate mofetil; EDM, electron-dense mesangial deposits; EDS, electron-dense subendothelial deposits; FK506, prograf/tacrolimus.
